EPS Bio TechnologyROCO:4183 63 EBITDA Margin % is 2.76% as of Dec. 2025, which is 70% below its 10-year median of 9.21. GuruFocus rates ROCO:4183 with a GF Score™ of 63/100 and a GF Value™ of NT$22.94 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, EPS Bio Technology ranks worse than 59.85% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. EPS Bio Technology's EBITDA for the
three
months ended in Dec. 2025 was NT$3.3 Mil. EPS Bio Technology's Revenue for the
three
months ended in Dec. 2025 was NT$119.2 Mil. Therefore, EPS Bio Technology's EBITDA margin for the quarter that ended in Dec. 2025 was 2.76%.
EPS Bio Technology (ROCO:4183) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
EPS Bio Technology EBITDA Margin % Related Terms
EPS Bio Technology EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for EPS Bio Technology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4183 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, EPS Bio Technology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EPS Bio Technology EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, EPS Bio Technology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where EPS Bio Technology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS Bio Technology (ROCO:4183) has a EBITDA Margin % of 2.76% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on EPS Bio Technology and its competitors. This is 70% below median its historical median of 9.21. Over the past decade, EPS Bio Technology's EBITDA Margin % has ranged from 1.52 to 12.60. According to the industry distribution chart, EPS Bio Technology ranks #489 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 59.9%.
Is EPS Bio Technology's EBITDA Margin % too high?
EPS Bio Technology's current EBITDA Margin % of 2.76% is 70% below median its 10-year median of 9.21. Over the past 10 years, this metric has ranged from a low of 1.52 to a high of 12.60. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. EPS Bio Technology's value of 2.76% is 62.9% below this industry median. Based on the distribution chart, EPS Bio Technology ranks #489 out of 817 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, EPS Bio Technology has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EPS Bio Technology's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, EPS Bio Technology ranks #489 out of 817 companies for EBITDA Margin %. This places EPS Bio Technology in the lower half of its industry. The industry median EBITDA Margin % is 7.44. EPS Bio Technology's value of 2.76% is 62.9% below this benchmark. Historically, EPS Bio Technology's own EBITDA Margin % has ranged from 1.52 to 12.60 over the past decade. While the company's 10-year median is 9.21 vs. the industry median of 7.44, EPS Bio Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EPS Bio Technology's current EBITDA Margin % of 2.76% is 62.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on EPS Bio Technology and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EPS Bio Technology's current EBITDA Margin % is 2.76%, which is 70% below median its own 10-year median of 9.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EPS Bio Technology stock overvalued right now?
Based on GuruFocus' analysis, EPS Bio Technology (ROCO:4183) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$22.94, compared to a current price of NT$14.00 — trading 39% below its estimated fair value. The current EBITDA Margin % is 2.76%, which is 70% below median its 10-year median of 9.21 and 62.9% below the Medical Devices & Instruments industry median of 7.44. EPS Bio Technology's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For EPS Bio Technology (ROCO:4183), the current EBITDA Margin % is 2.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EPS Bio Technology (ROCO:4183) Overvalued in 2026?
Based on GuruFocus' analysis, EPS Bio Technology stock appears to be undervalued.
The current stock price of NT$14.00 is trading 39% below its estimated GF Value™ of NT$22.94.
GuruFocus considers EPS Bio Technology to be Significantly Undervalued.
Key valuation signals for ROCO:4183:
EBITDA Margin %: 2.76% (70% below median its 10-year median of 9.21)
GF Value™: NT$22.94 vs. price of NT$14.00 (39% below fair value)
Industry Position: 62.9% below the Medical Devices & Instruments median (#489 of 817)
No single metric tells the full story. See the ROCO:4183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EPS Bio Technology Corp operates in medical equipment manufacturing, international trade, intellectual property, and research, design, development, manufacture and sale of blood glucose measuring system and cirrhosis testing system. Its products include Test sheet and Glucose machine. Geographically it operates in Germany, Iran, Kingdom of Saudi Arabia, Switzerland, Las Vegas, and Others with majority of the revenue deriving from Germany.
63GF Score
Get the complete analysis for ROCO:4183
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4183 has been successfully added to your 
